Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CTSD contributors: mct - updated : 25-10-2017
HGNC name cathepsin D
HGNC id 2529
ASSOCIATED DISORDERS
corresponding disease(s) CLN10
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
constitutional     --low  
reduced by approximately 50p100 in monocyte-derived macrophages of low HDL-C subjects, most significantly those with cholesterol efflux defects but without mutations in ABCA1
constitutional     --over  
significantly increased in the frontal cortex, in pyramidal and granule cells of the hippocampus, and in cerebellar neurons in autistic subjects as compared to controls
tumoral     --over  
in human breast carcinoma and many other tumor types
constitutional       loss of function
partial loss of CTSD activity is sufficient to cause a reduction in lysosomal function, which in turn leads to SNCA aggregation and propagation of the aggregates
constitutional germinal mutation      
increased lysosomal storage due to CTSD deficiency causes oxidative damage in brain pericytes, subsequently resulting in an increased vessel diameter, enhanced permeability of the BBB and the infiltration of peripheral blood mononuclear cells (PBMCs)
constitutional     --low  
reduced CTSD level is an important factor that may contribute to the pathogenesis of preeclampsia, possibly by inhibiting normal trophoblastic invasion
Susceptibility
  • almost a mild risk factor for sporadic Alzheimer disease (AD)
  • Variant & Polymorphism SNP
  • (rs17571) of the cathepsin D gene associated with increased AD risk, in men but not in women
  • Candidate gene
    Marker
  • with eEF1s are promising markers for the detection of cellular senescence induced by a variety of treatments (
  • Therapy target
    SystemTypeDisorderPubmed
    neurologyneurodegenerativeParkinson/dementia Parkinsonism
    upregulation of cathepsin D could be an additional therapeutic strategy to lessen alpha-synuclein burden in synucleinopathies
    cancer  
    inhibition of autophagy could be a novel strategy for the adjuvant chemotherapy of CTSD-expressing cancers
    ANIMAL & CELL MODELS
  • CtsD-deficient mice show severe visceral lesions like lymphopenia in addition to their central nervous system (CNS) phenotype of ceroid accumulation, microglia activation, and seizures